256 related articles for article (PubMed ID: 38555429)
1. The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification.
Weng L; Zhou J; Guo S; Xu N; Ma R
Cancer Cell Int; 2024 Mar; 24(1):120. PubMed ID: 38555429
[TBL] [Abstract][Full Text] [Related]
2. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype.
Jézéquel P; Lasla H; Gouraud W; Basseville A; Michel B; Frenel JS; Juin PP; Ben Azzouz F; Campone M
Breast Cancer; 2024 May; ():. PubMed ID: 38777987
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer.
Xiao Y; Ma D; Yang YS; Yang F; Ding JH; Gong Y; Jiang L; Ge LP; Wu SY; Yu Q; Zhang Q; Bertucci F; Sun Q; Hu X; Li DQ; Shao ZM; Jiang YZ
Cell Res; 2022 May; 32(5):477-490. PubMed ID: 35105939
[TBL] [Abstract][Full Text] [Related]
5. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.
Fan L; Wang ZH; Ma LX; Wu SY; Wu J; Yu KD; Sui XY; Xu Y; Liu XY; Chen L; Zhang WJ; Jin X; Xiao Q; Shui RH; Xiao Y; Wang H; Yang YS; Huang XY; Cao AY; Li JJ; Di GH; Liu GY; Yang WT; Hu X; Xia Y; Liang QN; Jiang YZ; Shao ZM
Lancet Oncol; 2024 Feb; 25(2):184-197. PubMed ID: 38211606
[TBL] [Abstract][Full Text] [Related]
6. Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping.
Hartung C; Porsch M; Stückrath K; Kaufhold S; Staege MS; Hanf V; Lantzsch T; Uleer C; Peschel S; John J; Pöhler M; Weigert E; Buchmann J; Bürrig KF; Schüler K; Bethmann D; Große I; Kantelhardt EJ; Thomssen C; Vetter M
Breast Care (Basel); 2021 Dec; 16(6):637-647. PubMed ID: 35082572
[TBL] [Abstract][Full Text] [Related]
7. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry-based molecular subtyping of triple-negative breast cancer and its prognostic significance.
Leeha M; Kanokwiroon K; Laohawiriyakamol S; Thongsuksai P
Pathol Oncol Res; 2023; 29():1611162. PubMed ID: 37274773
[No Abstract] [Full Text] [Related]
9. iTRAQ-Based Quantitative Proteomic Analysis Strengthens Transcriptomic Subtyping of Triple-Negative Breast Cancer Tumors.
Jézéquel P; Guette C; Lasla H; Gouraud W; Boissard A; Guérin-Charbonnel C; Campone M
Proteomics; 2019 Nov; 19(21-22):e1800484. PubMed ID: 30951236
[TBL] [Abstract][Full Text] [Related]
10. Molecular Classification Models for Triple Negative Breast Cancer Subtype Using Machine Learning.
Bissanum R; Chaichulee S; Kamolphiwong R; Navakanitworakul R; Kanokwiroon K
J Pers Med; 2021 Sep; 11(9):. PubMed ID: 34575658
[TBL] [Abstract][Full Text] [Related]
11. Triple-negative breast cancer: A run-through of features, classification and current therapies.
Manjunath M; Choudhary B
Oncol Lett; 2021 Jul; 22(1):512. PubMed ID: 33986872
[TBL] [Abstract][Full Text] [Related]
12. Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer.
Tong L; Yu X; Wang S; Chen L; Wu Y
Breast Cancer (Dove Med Press); 2023; 15():647-658. PubMed ID: 37644916
[TBL] [Abstract][Full Text] [Related]
13. High expression of TLR3 in triple-negative breast cancer predicts better prognosis-data from the Fudan University Shanghai Cancer Center cohort and tissue microarrays.
Fan L; Sui XY; Jin X; Zhang WJ; Zhou P; Shao ZM
BMC Cancer; 2023 Apr; 23(1):298. PubMed ID: 37005579
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapies in Triple-Negative Breast Cancer.
Marmé F; Schneeweiss A
Breast Care (Basel); 2015 Jul; 10(3):159-66. PubMed ID: 26557820
[TBL] [Abstract][Full Text] [Related]
15. Biology and Management of Patients With Triple-Negative Breast Cancer.
Sharma P
Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
[TBL] [Abstract][Full Text] [Related]
16. Current landscape of personalized clinical treatments for triple-negative breast cancer.
Zhang J; Xia Y; Zhou X; Yu H; Tan Y; Du Y; Zhang Q; Wu Y
Front Pharmacol; 2022; 13():977660. PubMed ID: 36188535
[TBL] [Abstract][Full Text] [Related]
17. Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021.
Bou Zerdan M; Ghorayeb T; Saliba F; Allam S; Bou Zerdan M; Yaghi M; Bilani N; Jaafar R; Nahleh Z
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267561
[TBL] [Abstract][Full Text] [Related]
18. Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features.
Vtorushin S; Dulesova A; Krakhmal N
J Zhejiang Univ Sci B; 2022 Aug; 23(8):617-624. PubMed ID: 35953756
[TBL] [Abstract][Full Text] [Related]
19. Subclassifying triple-negative breast cancers and its potential clinical utility.
Lian J; Ma HX; Xu EW; Bu P; Yun KM; Xi YF
Virchows Arch; 2022 Jul; 481(1):13-21. PubMed ID: 35471664
[TBL] [Abstract][Full Text] [Related]
20. Reassessment of Reliability and Reproducibility for Triple-Negative Breast Cancer Subtyping.
Yu X; Liu Y; Chen M
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
